This is a renewal application for a multidisciplinary hematology training program at New York University School of Medicine which has been in existence for over 42 years. The program is designed to provide two- year research opportunities for 5-6 post-doctoral fellows under the guidance of a faculty of 13 mentors. The training faculty consists of academic hematologists and hematopathologists with active laboratories applying basic science methods to the study of hematologic disorders as well as mentors of the basic science departments of NYU School of Medicine. There is abundant interaction among the faculty members within the program as well as with other scientists at this institution. The clinical research at this institution has been recognized by the NIH in its designation as a Comprehensive Cancer Center and an AIDS Center. The program director's research spans both areas. New faculty members have strengthened the basic science orientation of the program. The faculty works with this framework to train physician-scientists for future work in the academic community. A common theme of all the projects is their orientation to human disease.
These aims will be accomplished by training promising candidates in the design, execution and evaluation of experiments so that they may join the ranks of academic physician-scientists in basic as well as translational hematology research.

Public Health Relevance

As the Nation's population is aging, it is becomes even more necessary that we train physician-scientists in hematologic disorders in basic and translational research. The training program at NYU School of Medicine will continue that mission.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Chang, Henry
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
Internal Medicine/Medicine
Schools of Medicine
New York
United States
Zip Code
Saint Fleur-Lominy, Shella; Maus, Mate; Vaeth, Martin et al. (2018) STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia. Cell Rep 24:3045-3060.e5
Cullis, Jane; Siolas, Despina; Avanzi, Antonina et al. (2017) Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer. Cancer Immunol Res 5:182-190
Sayin, Volkan I; LeBoeuf, Sarah E; Singh, Simranjit X et al. (2017) Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. Elife 6:
Fehrenbacher, Nicole; Tojal da Silva, Israel; Ramirez, Craig et al. (2017) The G protein-coupled receptor GPR31 promotes membrane association of KRAS. J Cell Biol 216:2329-2338
Strazza, Marianne; Azoulay-Alfaguter, Inbar; Peled, Michael et al. (2017) PLC?1 regulates SDF-1?-induced lymphocyte adhesion and migration to sites of inflammation. Proc Natl Acad Sci U S A 114:2693-2698
Pyzer, A R; Stroopinsky, D; Rosenblatt, J et al. (2017) MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia 31:2780-2790
Romero, Rodrigo; Sayin, Volkan I; Davidson, Shawn M et al. (2017) Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med 23:1362-1368
Bar-Natan, Michal; Stroopinsky, Dina; Luptakova, Katarina et al. (2017) Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol 176:929-938
Xiang, Michael; Kim, Haesook; Ho, Vincent T et al. (2016) Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood 128:1845-1853
Santori, Fabio R; Huang, Pengxiang; van de Pavert, Serge A et al. (2015) Identification of natural ROR? ligands that regulate the development of lymphoid cells. Cell Metab 21:286-298

Showing the most recent 10 out of 45 publications